Talphera (TLPH) Interest & Investment Income (2011 - 2026)
Talphera's (TLPH) quarterly Interest & Investment Income came in at $169000.0 in Q1 2026, up 144.93% year-on-year from $69000.0 in Q1 2025, and down 16.75% quarter-over-quarter from $203000.0 in Q4 2025.
Talphera (TLPH) Interest & Investment Income (2011 - 2026) Analysis & Trends
Talphera's Interest & Investment Income history runs 16 years deep, the most recent figure standing at $169000.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 144.93% year-over-year to $169000.0 in Q1 2026; TTM through Mar 2026 was $536000.0, a 1.52% increase from a year earlier, with the FY2025 full-year figure at $436000.0, down 35.79% from the prior year.
- Interest & Investment Income retreated to $169000.0 in Q1 2026 per TLPH's latest filing, from $203000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $858000.0 in Q2 2023 and bottomed at $38000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $147500.0 (2022), against an average of $179125.0.
- Across the five-year window, Interest & Investment Income jumped 1582.35% in 2023 and plunged 76.57% in 2024, its largest moves.
- Year by year, Interest & Investment Income stood at $137000.0 in 2022, then climbed by 24.82% to $171000.0 in 2023, then sank by 39.77% to $103000.0 in 2024, then soared by 97.09% to $203000.0 in 2025, then dropped by 16.75% to $169000.0 in 2026.
- Per Business Quant, the three latest TLPH Interest & Investment Income figures stand at $169000.0 (Q1 2026), $203000.0 (Q4 2025), and $81000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Talphera | 87.63 Mn | 87.63 Mn | - | 169,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 169,000.00 |
| Dec 31, 2025 | 203,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 83,000.00 |
| Mar 31, 2025 | 69,000.00 |
| Dec 31, 2024 | 103,000.00 |
| Sep 30, 2024 | 155,000.00 |
| Jun 30, 2024 | 201,000.00 |
| Mar 31, 2024 | 220,000.00 |
| Dec 31, 2023 | 171,000.00 |
| Sep 30, 2023 | 187,000.00 |
| Jun 30, 2023 | 858,000.00 |
| Dec 31, 2022 | 137,000.00 |
| Sep 30, 2022 | 140,000.00 |
| Jun 30, 2022 | 51,000.00 |
| Mar 31, 2022 | 38,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 32,000.00 |
| Jun 30, 2021 | -16,000.00 |
| Mar 31, 2021 | 76,000.00 |